

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Shapiro David</u> _____ (Last) (First) (Middle) C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET _____ (Street) NEW YORK NY 10013 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>INTERCEPT PHARMACEUTICALS INC [ICPT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CMO and EVP - Development</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/09/2013</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock	04/09/2013		M ⁽¹⁾		3,750	A	\$10.4001	3,750	D	
Common stock	04/09/2013		S ⁽¹⁾		50	D	\$33.86	3,700	D	
Common stock	04/09/2013		S ⁽¹⁾		200	D	\$34.25	3,500	D	
Common stock	04/09/2013		S ⁽¹⁾		100	D	\$34.29	3,400	D	
Common stock	04/09/2013		S ⁽¹⁾		300	D	\$34.3	3,100	D	
Common stock	04/09/2013		S ⁽¹⁾		300	D	\$34.31	2,800	D	
Common stock	04/09/2013		S ⁽¹⁾		100	D	\$34.32	2,700	D	
Common stock	04/09/2013		S ⁽¹⁾		100	D	\$34.3268	2,600	D	
Common stock	04/09/2013		S ⁽¹⁾		200	D	\$34.35	2,400	D	
Common stock	04/09/2013		S ⁽¹⁾		200	D	\$34.375	2,200	D	
Common stock	04/09/2013		S ⁽¹⁾		100	D	\$34.38	2,100	D	
Common stock	04/09/2013		S ⁽¹⁾		2,100	D	\$34.5	0	D	
Common stock	04/09/2013		M		8,113 ⁽³⁾	A	(2)	8,113	D	
Common stock	04/09/2013		F ⁽⁴⁾		3,049	D	\$34.57	5,064	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(2)	04/09/2013		M			8,113 ⁽³⁾	(3)	(3)	Common stock	8,113	\$0	17,848	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to Purchase Common Stock	\$10.4001	04/09/2012		M ⁽¹⁾			3,750	(5)	04/01/2018	Common stock	3,750	\$0	82,788	D	

Explanation of Responses:

- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2013.
- Conversion of restricted stock units ("RSUs") to shares of common stock on a one-for-one basis.
- On November 16, 2012, the reporting person was granted 25,961 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 31.25% of the shares underlying the RSUs, became vested on April 9, 2013, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares originally underlying the RSUs will vest pro rata on a quarterly basis from April 1, 2013 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
- Net share settlement of RSUs to cover tax withholding obligations.
- All shares underlying this option have vested.

/s/ Bryan Yoon, as attorney-in-fact 04/11/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.